.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX25_BaloxavirMarboxil.BaloxavirMarboxil .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX25_BaloxavirMarboxil.BaloxavirMarboxil| name: | BaloxavirMarboxil |
| ATC code: | J05AX25 | route: | oral |
| n-compartments | 2 |
Baloxavir marboxil is an antiviral prodrug used in the treatment of influenza A and B. It inhibits the cap-dependent endonuclease activity of the viral polymerase, blocking viral replication. Approved and currently used for the treatment of acute, uncomplicated influenza in otherwise healthy adults and adolescents.
Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose.
Liu, Y, et al., & De Buck, S (2022). Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals. Clinical and translational science 15(5) 1196–1203. DOI:10.1111/cts.13237 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35176206
Kim, Y, et al., & Lee, S (2022). Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects. Clinical and translational science 15(2) 422–432. DOI:10.1111/cts.13160 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34664769
Retout, S, et al., & Cosson, V (2022). A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B. Clinical pharmacology and therapeutics 112(2) 372–381. DOI:10.1002/cpt.2648 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35585696